Author Correction: Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-03-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-023-37338-7 |
| _version_ | 1827979465285697536 |
|---|---|
| author | Michal Canetti Noam Barda Mayan Gilboa Victoria Indenbaum Michal Mandelboim Tal Gonen Keren Asraf Yael Weiss-Ottolenghi Sharon Amit Ram Doolman Ella Mendelson Dror Harats Laurence S. Freedman Yitshak Kreiss Yaniv Lustig Gili Regev-Yochay |
| author_facet | Michal Canetti Noam Barda Mayan Gilboa Victoria Indenbaum Michal Mandelboim Tal Gonen Keren Asraf Yael Weiss-Ottolenghi Sharon Amit Ram Doolman Ella Mendelson Dror Harats Laurence S. Freedman Yitshak Kreiss Yaniv Lustig Gili Regev-Yochay |
| author_sort | Michal Canetti |
| collection | DOAJ |
| first_indexed | 2024-04-09T21:37:08Z |
| format | Article |
| id | doaj.art-b77aada362984862a06b4ee7d1f26b58 |
| institution | Directory Open Access Journal |
| issn | 2041-1723 |
| language | English |
| last_indexed | 2024-04-09T21:37:08Z |
| publishDate | 2023-03-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Nature Communications |
| spelling | doaj.art-b77aada362984862a06b4ee7d1f26b582023-03-26T11:14:34ZengNature PortfolioNature Communications2041-17232023-03-011411110.1038/s41467-023-37338-7Author Correction: Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-upMichal Canetti0Noam Barda1Mayan Gilboa2Victoria Indenbaum3Michal Mandelboim4Tal Gonen5Keren Asraf6Yael Weiss-Ottolenghi7Sharon Amit8Ram Doolman9Ella Mendelson10Dror Harats11Laurence S. Freedman12Yitshak Kreiss13Yaniv Lustig14Gili Regev-Yochay15The Infection Prevention & Control Unit, Sheba Medical Center, Tel HashomerARC Innovation Center, Sheba Medical Center, Tel HashomerThe Infection Prevention & Control Unit, Sheba Medical Center, Tel HashomerSackler School of Medicine, Tel-Aviv UniversitySackler School of Medicine, Tel-Aviv UniversityThe Infection Prevention & Control Unit, Sheba Medical Center, Tel HashomerSackler School of Medicine, Tel-Aviv UniversityThe Infection Prevention & Control Unit, Sheba Medical Center, Tel HashomerSackler School of Medicine, Tel-Aviv UniversitySackler School of Medicine, Tel-Aviv UniversitySackler School of Medicine, Tel-Aviv UniversityGeneral Management, Sheba Medical Center, Tel HashomerBiostatistics and Biomathematics Unit, Gertner Institute of Epidemiology and Health Policy Research, Sheba Medical CenterSackler School of Medicine, Tel-Aviv UniversitySackler School of Medicine, Tel-Aviv UniversityThe Infection Prevention & Control Unit, Sheba Medical Center, Tel Hashomerhttps://doi.org/10.1038/s41467-023-37338-7 |
| spellingShingle | Michal Canetti Noam Barda Mayan Gilboa Victoria Indenbaum Michal Mandelboim Tal Gonen Keren Asraf Yael Weiss-Ottolenghi Sharon Amit Ram Doolman Ella Mendelson Dror Harats Laurence S. Freedman Yitshak Kreiss Yaniv Lustig Gili Regev-Yochay Author Correction: Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up Nature Communications |
| title | Author Correction: Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up |
| title_full | Author Correction: Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up |
| title_fullStr | Author Correction: Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up |
| title_full_unstemmed | Author Correction: Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up |
| title_short | Author Correction: Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up |
| title_sort | author correction immunogenicity and efficacy of fourth bnt162b2 and mrna1273 covid 19 vaccine doses three months follow up |
| url | https://doi.org/10.1038/s41467-023-37338-7 |
| work_keys_str_mv | AT michalcanetti authorcorrectionimmunogenicityandefficacyoffourthbnt162b2andmrna1273covid19vaccinedosesthreemonthsfollowup AT noambarda authorcorrectionimmunogenicityandefficacyoffourthbnt162b2andmrna1273covid19vaccinedosesthreemonthsfollowup AT mayangilboa authorcorrectionimmunogenicityandefficacyoffourthbnt162b2andmrna1273covid19vaccinedosesthreemonthsfollowup AT victoriaindenbaum authorcorrectionimmunogenicityandefficacyoffourthbnt162b2andmrna1273covid19vaccinedosesthreemonthsfollowup AT michalmandelboim authorcorrectionimmunogenicityandefficacyoffourthbnt162b2andmrna1273covid19vaccinedosesthreemonthsfollowup AT talgonen authorcorrectionimmunogenicityandefficacyoffourthbnt162b2andmrna1273covid19vaccinedosesthreemonthsfollowup AT kerenasraf authorcorrectionimmunogenicityandefficacyoffourthbnt162b2andmrna1273covid19vaccinedosesthreemonthsfollowup AT yaelweissottolenghi authorcorrectionimmunogenicityandefficacyoffourthbnt162b2andmrna1273covid19vaccinedosesthreemonthsfollowup AT sharonamit authorcorrectionimmunogenicityandefficacyoffourthbnt162b2andmrna1273covid19vaccinedosesthreemonthsfollowup AT ramdoolman authorcorrectionimmunogenicityandefficacyoffourthbnt162b2andmrna1273covid19vaccinedosesthreemonthsfollowup AT ellamendelson authorcorrectionimmunogenicityandefficacyoffourthbnt162b2andmrna1273covid19vaccinedosesthreemonthsfollowup AT drorharats authorcorrectionimmunogenicityandefficacyoffourthbnt162b2andmrna1273covid19vaccinedosesthreemonthsfollowup AT laurencesfreedman authorcorrectionimmunogenicityandefficacyoffourthbnt162b2andmrna1273covid19vaccinedosesthreemonthsfollowup AT yitshakkreiss authorcorrectionimmunogenicityandefficacyoffourthbnt162b2andmrna1273covid19vaccinedosesthreemonthsfollowup AT yanivlustig authorcorrectionimmunogenicityandefficacyoffourthbnt162b2andmrna1273covid19vaccinedosesthreemonthsfollowup AT giliregevyochay authorcorrectionimmunogenicityandefficacyoffourthbnt162b2andmrna1273covid19vaccinedosesthreemonthsfollowup |